SCHEMBL4140385

SCHEMBL4140385

CCOC(=O)c1ccc2c(c1)nc(-c1ccc3nc(C(=O)NC4(c5ccc(Cl)cc5)CCCCC4)ccc3c1)n2C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.40
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
SIRT2 Q8IXJ6 7/20 0.38
SIRT1 Q96EB6 6/20 0.38
YEATS4 O95619 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIRT3 Q9NTG7 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRL1 P41146 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119939 0.90 L3MBTL1 (0.47) KCNH2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4137916 0.89 MAPT (0.46) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4125616 0.86 BMPR2 (0.44) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4518317 0.85 RPS6KB1 (0.42) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL5776100 0.83 SIRT2 (0.45) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4123368 0.83 L3MBTL1 (0.51) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4140386 0.82 SIRT2 (0.42) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4124652 0.82 SIRT2 (0.42) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4118974 0.81 RPS6KB1 (0.44) RPS6KB1TP53MAPTRXFP1SIRT2
SCHEMBL4124971 0.80 L3MBTL1 (0.48) RPS6KB1TP53MAPTRXFP1SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 US disclosed
US-20050187390-A1 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES HAVCR2, MAVS, ZC3HAV1 RPS6KB1 3007/4885TP53 2428/4885MAPT 2748/4885
US-20050187390-A1 Bicyclic heteroaryl derivatives HAVCR2, MAVS, ZC3HAV1 RPS6KB1 3007/4885TP53 2428/4885MAPT 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.